Safety, Efficacy, and Visual Performance of an Orthokeratology Lens with Increased Compression Factor

The aim was to evaluate the safety, efficacy, and visual performance of an orthokeratology lens with an increased compression factor (ICF) of 1.25 D in a 3-month follow-up. Thirty-six myopic patients (5 males and 31 females; 24.2 ± 5.8 years) were fitted with Alexa AR (Tiedra Farmacéutica S.L., Madrid, Spain) contact lenses (CLs) and twenty participants finished the follow-up. Visual acuity (VA), subjective refraction, primary spherical and primary coma aberrations, keratometry, central pachymetry, and ocular surface evaluation were performed at baseline and after 1 night, 1 week, 1 month, and 3 months of CL wear. The differences among visits were analyzed using a repeated-measures analysis of variance or the Friedman test. The spherical equivalent decreased (p ≤ 0.005), and the uncorrected VA improved (p < 0.001) until the first week. Corneal and ocular aberrations showed a significant increase (p ≤ 0.02). A significant decrease (p < 0.001) was found for keratometry values. No significant changes were observed in either central pachymetry or ocular surface parameters among study visits. In conclusion, an orthokeratology CL with an ICF of 1.25 D provides good safety, efficacy, and visual performance in a 3-month follow-up. Seven days of orthokeratology wear are enough to achieve the full myopic compensation, resulting in satisfactory VA. ; E.M.-P., A.M.-M., and D.P.P. received funding from Tiedra Farmacéutica S.L. within the framework of the research project TIEDRA1-21A in collaboration with the University of Alicante. Likewise, these authors received funding from Centro Internacional para la Investigación del Envejecimiento, Fundación de la Comunidad Valenciana (ICAR) for the performance of this research within the framework of the research project PRESBYSIM. Furthermore, E.M.-P. has been also supported by the European Union—NextGenerationEU (Orden UNI/551/2021; CONVREC-2021-18).